Search Results - woo-jin+song

3 Results

Sort By:

Integrated Proteomic Biomarkers for the Detection of Aggressive Prostate Cancer

Unmet Need / Invention Novelty: Current prostate-specific antigen (PSA)-based tests lack specificity in differentiating between aggressive and non-aggressive prostate cancer (PC), the latter of which does not require invasive intervention or treatment. Aggressive prostate cancer is therefore over-diagnosed and overtreated. There is an unmet need to...

Published: 9/27/2024 | Inventor(s): Daniel Chan, Zhen Zhang, Lori Sokoll, Jin Song, Shiyong Ma, Hui Zhang

Keywords(s):

Category(s): Clinical and Disease Specializations > Oncology > Prostate Cancer, Technology Classifications > Diagnostics > Biomarkers

Hepatic Kisspeptin Secretion Impairs Insulin Secretion from Pancreatic Bets Cell. Kisspeptin Receptor GPR54 Antagonist for Treatment of Prediabetes and Diabetes Mellitus in Humans.

Unmet NeedGlucagon and insulin work together to keep blood glucose levels balanced. Glucagon stimulates the liver to secrete glucose while insulin suppresses glucose release. If the body does not regulate glucose levels properly, Type 2 diabetes mellitus (T2DM) will develop. Type 2 diabetes mellitus is a world-wide epidemic, projected to affect 1/3...

Published: 9/26/2024 | Inventor(s): Woo-Jin Song, Prosenjit Mondal, Mehboob Hussain

Keywords(s): Biomarker, Diabetes, Disease Indication, Mechanism-of-action Biomarker, Metabolic Disorders, Therapeutic Matter, Therapeutics, Type 2 Diabetes, Type II Diabetes

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Metabolic Diseases, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Therapeutic Modalities > Targets, Clinical and Disease Specializations > Diabetes, Technology Classifications > Diagnostics, Technology Classifications > Therapeutic Modalities, Clinical and Disease Specializations > Diabetes > Type 2 Diabetes

Development of magnetic bead-based multiplex immunoassays of serum biomarkers for the early detection of pancreatic cancer

Pancreatic cancer is the 4th leading cause of cancer death in the United States. The majority of patients present with unresectable disease leading a median survival of 6 months and an overall 5-year survival of < 5%. The early detection of this disease is critical because surgery at an early stage is the most promising therapy that could greatly...

Published: 9/26/2024 | Inventor(s): Jin Song, Zhen Zhang, Daniel Chan

Keywords(s): Adenocarcinoma, Assay, Biomarker, Cancers, Clinical Diagnostics, Diagnostic Biomarker, Disease Indication, In Vitro Diagnostics, Pancreatic Cancer, Pancreatic ductal adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Sample Prep Method

Category(s): Clinical and Disease Specializations, Clinical and Disease Specializations > Gastroenterology, Clinical and Disease Specializations > Oncology > Adenocarcinoma, Clinical and Disease Specializations > Oncology > Pancreatic Cancer, Clinical and Disease Specializations > Oncology > Pancreatic Ductal Adenocarcinoma, Technology Classifications > Diagnostics > Biomarkers, Technology Classifications > Diagnostics > Diagnostic Biomarkers, Technology Classifications > Diagnostics > In Vitro Diagnostics, Technology Classifications > Research Tools > Assays, Technology Classifications > Diagnostics, Clinical and Disease Specializations > Oncology, Technology Classifications > Research Tools